The paper reports on rate and type of @entity715 events occurring during the observational, prospective, inception-cohort, multicenter ISCOAT study. 2,745 unselected, daily practice @entity1 , consecutively referring to 34 Italian anticoagulation clinics to monitor the oral anticoagulant treatment, were included in the study from beginning of their first anticoagulant course. During a total follow-up of 2,011 @entity1 -years of treatment 70 @entity715 events (3.5 per 100 @entity1 years) were recorded in 67 @entity1 : 20 fatal (1%), 39 major (1.9%) and 11 minor (0.6%). 34/70 events occurred within the first 90 days of treatment (relative risk - at multivariate analysis - of < or =90 days vs. >90 = 20.6, C.I. 12.7-33.5; p <0.0001). The risk was higher in @entity1 aged > or =70 y (1.62, C.I. 1.0-2.61; p <0.05), and when indication for anticoagulant treatment was @entity3657 (1.84, C.I. 1.01-3.36; p <0.05). The frequency of @entity715 events was 17.5% when international normalised ratio (INR) levels were < 1.5, decreasing to 2.3% for INRs within the 2-2.99 category (relative risk of INRs <2.0 vs. > or =2 = 1.88, C.I. 1.16-3.07; p <0.05). The recorded rate of @entity715 events was lower than that reported in the few available studies. A greater risk should be expected during the first 90 days of treatment, when anticoagulation levels are <2.0 INR, in @entity1 > 70 years and in those with @entity3657 .

XXXX events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic'] @entity3657 :: ('MESH:D058729', 'Disease') :: ['peripheral/cerebral arterial disease', 'cerebrovascular/peripheral arterial disease']
@entity715 :: (MESH:D013927,Disease) :: ['Thrombotic']
